A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer - Concepedia

Concepedia

Publication | Open Access

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

DOI Full Paper Access

59

Citations

32

References

2019

Year

Margaret E. Gatti‐Mays, Jason M. Redman, Renee N. Donahue, Claudia Palena, Ravi A. Madan, Fatima Karzai, Marijo Bilušić, Houssein Abdul Sater, Jennifer L. Marté, Lisa M. Cordes,

Abstract

Concurrent ETBX-011, ETBX-051, and ETBX-061 can be safely administered to patients with advanced cancer. Further studies of the vaccine regimen in combination with other agents, including immune checkpoint blockade, are planned.

References

	Year	Citations

Page 1